PaxMedica, Inc.PaxMedica, Inc.PaxMedica, Inc.

PaxMedica, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪1.63 M‬USD
−10.5341USD
‪−18.29 M‬USD
‪6.79 M‬
Beta (1Y)
−2.56

About PaxMedica, Inc.

CEO
Howard J. Weisman
Headquarters
Tarrytown
Employees (FY)
7
Founded
2018
FIGI
BBG00VVV2P55
PaxMedica, Inc. is a clinical stage biopharmaceutical company. It engages in the business of developing drug candidates for the treatment of autism spectrum disorder, Fragile X syndrome tremor-ataxia, and Human African Trypanosomiasis. The company was founded by Michael L. Derby on April 5, 2018 and is headquartered in Tarrytown, NY.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of PXMD is 0.2200 USD — it hasn't changed in the past 24 hours. Watch PaxMedica, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange PaxMedica, Inc. stocks are traded under the ticker PXMD.
PXMD stock has fallen by 6.38% compared to the previous week, the month change is a 29.78% fall, over the last year PaxMedica, Inc. has showed a 99.90% decrease.
PXMD reached its all-time high on Aug 26, 2022 with the price of 3031.1430 USD, and its all-time low was 0.2010 USD and was reached on May 8, 2024. View more price dynamics on PXMD chart.
See other stocks reaching their highest and lowest prices.
PXMD stock is 9.26% volatile and has beta coefficient of −2.56. Track PaxMedica, Inc. stock price on the chart and check out the list of the most volatile stocks — is PaxMedica, Inc. there?
Yes, you can track PaxMedica, Inc. financials in yearly and quarterly reports right on TradingView.
PaxMedica, Inc. is going to release the next earnings report on Aug 7, 2024. Keep track of upcoming events with our Earnings Calendar.
PXMD net income for the last quarter is ‪−3.69 M‬ USD, while the quarter before that showed ‪−5.92 M‬ USD of net income which accounts for 37.62% change. Track more PaxMedica, Inc. financial stats to get the full picture.
No, PXMD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 27, 2024, the company has 7.00 employees. See our rating of the largest employees — is PaxMedica, Inc. on this list?
Like other stocks, PXMD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PaxMedica, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PaxMedica, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PaxMedica, Inc. stock shows the sell signal. See more of PaxMedica, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.